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This study aimed to evaluate whether resveratrol (RSV) and its microbial metabolites
dihydro-resveratrol (DHR) and lunularin (LUN) affected fatty acid metabolism and
omega-3 polyunsaturated fatty acid (n3-PUFA) synthesis in cultured hepatocytes. To this
end, cultured human HepG2 hepatocytes were treated with non-toxic concentrations
of these polyphenols (40µM) and ∆5- and ∆6-desaturase (FADS1 and FADS2,
respectively) expression was measured. Resveratrol induced both genes but DHR and
LUN showed no effect. Co-incubation of RSV with α-linolenic acid (ALA) also induced
FADS1 and FADS2 expression. Moreover, transcription of carnitine palmitoyltransferase
1A and fatty acid synthase expression was increased, indicating induction of β-oxidation
and fatty acid synthesis, respectively. Using gas chromatography to measure fatty acid
levels, we observed the impact of RSV with and without ALA treatment on fatty acid
composition. However, RSV reduced unsaturated while increasing saturated fatty acid
levels. We found lower amounts of monounsaturated fatty acids (16:1n-7c, 18:1n-9c,
18:1n7c, and 20:1n-9) and n3-PUFA docosahexaenoic acid whereas unsaturated fatty
acid levels, especially of stearic acid, were elevated. Of interest, once we co-incubated
the cells with RSV together with bovine serum albumin, we found no differences in gene
expression compared to cells without RSV treatment. Although we found no positive
effect of RSV on n3-PUFA synthesis, the stilbene could possibly prevent cellular stress
by decreasing unsaturated fatty acid levels.
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INTRODUCTION
Consumption of omega-3-fatty-acid-rich foods (1), such as fish, walnuts, or algae (2, 3) may
decrease cardiovascular disease risk. The most important omega-3 long-chain polyunsaturated
fatty acids (n3-PUFA) are eicosapentaenoic acid (C20:5n-3; EPA) and docosahexaenoic acid
(C22:6n-3; DHA). General recommendations of EPA and DHA consumption vary between 250
and 1,000mg per day for healthy adults (4). Atlantic salmon (Salmo salar) contains approximately
two grams of long chain PUFAs per 100 g, with farmed fish usually containing higher lipid and thus
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PUFA levels than wild fish (5). However, aquaculture cannot
fully compensate for the decreasing amounts of wild fish and
the increasing demand due to growing world population (6).
Therefore, developing supplements or functional foods that
favor the synthesis of n3-PUFAs from their essential precursor
α-linolenic acid (C18:3n-3; ALA) (7) in humans could possibly
be an alternative to fish oil consumption per se.
Synthesis of PUFAs (Figure 1) mainly occurs in liver (11).
Here, fatty acid desaturases 1 and 2 (FADS1 and FADS2,
respectively) insert double bonds into the carbon chains of EPA
and DHA precursors. FADS1 adds a double bond to C20:4n-3
whereas FADS2 is responsible for desaturating ALA, C20:3n-3,
and C24:5n-3 (12). FADS2 can desaturate at the 16- and 18-
position and thus convert ALA to C18:4n-3 and C20:3n-3 to
C20:4n-3 (13, 14). Desaturation at the 18-position is exclusively
conducted by FADS2 (15).
Transcription factors regulating FADS1 and FADS2 gene
expression are proliferator-activated receptor alpha (PPARα)
(8), liver X receptor and sterol regulatory element binding
protein-1c (SREBP-1c) (16). They are regulated by external
ligands and cofactors and may induce or inhibit each other
(17–20). Moreover, EPA and fasting conditions possibly activate
PPARα, whereas C18:1n-9, ALA, C22:5n-3, and DHA impede
its action (20). Interestingly and in contrast to regulation of
PPARα, EPA and states of hunger have been shown to inhibit
SREBP-1c (21). Further PPARα targets have been reported to
code for proteins involved in β-oxidation such as carnitine
palmitoyltransferase 1A (CPT1) (8). Thereby, the risks because
of high levels of unsaturated phospholipids in the cell membrane
and, consequently, oxidative damage may be lowered (22, 23).
Resveratrol (RSV) is a plant derived stilbene (Figure 1C)
found in grapes and other fruits [reviewed by (24)]. Studies on
the polyphenol have reported protective effects against coronary
heart diseases [reviewed by (25)], antioxidant activities (26)
and other effects that partly mimic those of caloric restriction
[reviewed by (27)]. Furthermore, it has been hypothesized that
RSV may activate PPARα (via the 4’-OH group; Figure 1C) (28).
Thus, RSV may affect n3-PUFA synthesis (29–32).
In the gut, RSV was shown to be metabolized with type and
amount of derivatives varying greatly inter- and intraspecifically.
In humans, depending on the microbiota composition, RSV is
metabolized to dihydro-resveratrol (DHR) and may be further
metabolized to lunularin (LUN), both of which contain the
potentially PPARα-mediating 4’-OH group (Figures 1D,E) (33).
Low concentrations of DHR have been reported as showing
proliferative actions whereas higher amounts, similar to RSV,
are possibly rather antiproliferative agents (34). Furthermore,
low doses of DHR may decrease cholesterol accumulation by
inhibiting fatty acid binding protein 4 (35).
Abbreviations: ALA, α-linolenic acid; BSA, bovine serum albumin; CPT1,
carnitine palmitoyltransferase 1A; DHA, docosahexaenoic acid; DHR, dihydro-
resveratrol; EPA, eicosapentaenoic acid; EtOH, ethanol; FADS, fatty acid
desaturase; FAME, Fatty acid methyl ester; FASN, fatty acid synthase; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; n3-PUFA, omega-3 polyunsaturated
fatty acid; LUN, lunularin; PPAR, peroxisome proliferator-activated receptor; RSV,
resveratrol; SREBP-1c, sterol regulatory element binding protein-1c.
In order to compare how RSV and its gut metabolites
DHR and LUN affect FADS1 and FADS2 expression, we
included all three polyphenols in our experiments. In
addition, due to the positive effects reported for RSV on
fatty acid metabolism, we aimed to determine the potential
of RSV and its derivatives DHR and LUN to modulate




α-Linolenic acid was obtained from Sigma-Aldrich, Buchs,
Switzerland. Resveratrol (IUPAC name: 5-[(E)-2-(4-
hydroxyphenyl)ethenyl] benzene-1,3-diol; C14H12O3; CAS
number 501-36-0; purity ≥98%) was provided by Carl Roth
(Karlsruhe, Germany). Dihydro-resveratrol (IUPAC name:
5-[2-(4-hydroxyphenyl)ethyl] benzene-1,3-diol; C14H14O3;
CAS number 58436-28-5; purity ≥98%) was synthesized
according to Faragher et al. (36) and LUN (IUPAC name:
3-[2-(4-hydroxyphenyl)ethyl] phenol; C14H14O2; CAS number
37116-80-6; purity >97%) was obtained from Ark Pharm, Inc.
(Illinois, USA).
Cell Culture
HepG2 cells (IAZ, Munich, Germany; ATCC No: CCL-23) were
cultured in RPMI-1640 with L-glutamine (PAN Biotech,
Aidenbach, Germany). The passage number was ≤25.
The medium was supplemented with 10% (vol/vol) heat
inactivated fetal bovine serum (GibcoTM by Thermo Fisher
Scientific GmbH, life technologiesTM, Darmstadt, Germany)
and 1% penicillin/streptomycin (PAN Biotech, Aidenbach,
Germany). Cells were grown at 37◦C in a humidified 5%
CO2 incubator in T75 or T175 flasks (37). Cytotoxicity
was tested with a neutral red assay (38). To make results
comparable, RSV, DHR, and LUN were used at the same
non-toxic concentration of 40µM. Cells were treated at 80%
confluence for periods indicated in the subsequent sections.
Test compounds were dissolved in dimethyl sulfoxide (DMSO).
For co-incubation experiments, 40mM stock solutions of
ALA in EtOH were used to give a final ALA concentration
of 50µM. In all cases, incubations were carried out in
duplicate. Experiments were independently performed three
times.
RNA-Isolation and Quantitative Real Time
(qRT) Polymerase Chain Reaction (PCR)
Cells were treated with 40µM compounds; in the case of
RSV with or without co-incubation with ALA. After 24 h of
treatment, cells were harvested with peqGOLD TriFast and
RNA was isolated according to the manufacturer’s protocol
(peqGOLD TriFast, VWR International, Radnor, USA). Sample
RNA-concentrations and quality were determined with a Nano
Drop 2000 (Thermo Fisher Scientific GmbH, life technologiesTM,
Darmstadt, Germany). The A260 was used to calculate RNA
concentrations. The ratio of absorbance at 260 and 280 nm
was used to assess of RNA purity. Samples were frozen at
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FIGURE 1 | Hepatic endogenous synthesis of long-chain polyunsaturated fatty acids (PUFA) via fatty acid desaturases 1 and 2 (FADS1 and FADS2, respectively)
(A,B) and test compounds used in the study (C–E). (A) step of omega-6 PUFA synthesis regulated via FADS2; (B) steps of the two possible pathways of omega-3
PUFA synthesis from α-linolenic acid (C18:3n-3/ALA). α-linolenic acid is either first desaturated by fatty acid desaturase 6 (FADS2) and then elongated by elongase of
very long-chain fatty acids 5 (ELOVL5) or first elongated and then desaturated before being desaturated to eicosapentaenoic acid (C20:5n-3/EPA). Synthesis of
docosahexaenoic acid (C22:6n-3/DHA) requires further elongation and desaturation and a final peroxisomal step of β-oxidation (8–10). (C–E) Chemical structures of
resveratrol, dihydro-resveratrol and lunularin. Green marking indicates potentially responsible OH-groups for induction of peroxisome proliferator-activated receptor
alpha.
−80◦C at a concentration of 100 ng/µl and the 260/280
ratio was ≥1.8. The ratios for all samples can be found in
Supplementary Material. Gene expression was analyzed via
quantitative real time polymerase chain reaction (qRT-PCR) with
SensiFASTTM SYBR R© No-ROX One-Step Kit (Bioline GmbH,
Luckenwalde, Germany) using a Rotorgene 6000 cycler (Corbett
Life Science, Sydney, Australia). To this end, samples were
diluted with nuclease free water and the qRT-PCR reagents
to a final concentration of 0.2 ng/µl. Sequences of used
primers FADS1, FADS2, CPT1, fatty acid synthase (FASN), and
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) are given in Table 1. Primers for FADS1, FADS2,
CPT1, and GAPDH were self-designed using Primer3web. The
FASN primer was obtained from the Harvard Primer Bank
(PrimerBank ID 41872630c1) (39).
The expression levels of the target genes were determined
by normalizing the calculated relative concentrations to the
housekeeping gene GAPDH.
Western Blotting Analyses
Cells were treated with 40µM of RSV with or without ALA
for 24 h. For protein analysis, whole cell protein lysates
from HepG2 were harvested with RIPA buffer (50 mmol/l
Tris, 150 mmol/l NaCl, 0.5% sodium deoxycholate (v/v),
0.1% SDS (w/v), 1% NP-40 (v/v), pH 7.4) supplemented
with proteinase inhibitors. Protein concentrations were
determined with the PierceTM BCA assay (Thermo Fisher
Scientific GmbH, life technologiesTM, Darmstadt, Germany)
according to the manufacturer’s instructions and analyzed by
Western Blotting analysis as described before (40). Briefly,
30 µg per samples were heated with loading buffer and
applied to Mini-PROTEAN R© StainfreeTM Precast Gels (4–20%,
BioRad laboratories GmbH, Munich, Germany). Samples
were transferred to a polyvinylidenedifluoride membrane
(Bio-Rad laboratories GmbH, Munich, Germany) and blocked
with skim milk dissolved in Tris-buffered saline + 0.05%
(v/v) Tween 20. Membranes were then incubated with the
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TABLE 1 | Sequences of primers used in this study.
Gene name Sequence forward Sequence reverse
GAPDH—Glyceraldehyde-3-phosphate dehydrogenase CAATGACCCCTTCATTGACC GATCTCGCTCCTGGAAGATG
FADS1—fatty acid desaturase 1 GATGCCTCGACACAATTACC CTGCCCTGACTCCTTTAGTG
FADS2—fatty acid desaturase 2 ACAAGGATCCCGATGTGAAC TTCGTGCTGGTGATTGTAGG
CPT1—carnitine palmitoyltransferase 1A CTGCTTTACAGGCGCAAACT TCATGTGCTGGATGGTGTCT
FASN—fatty acid synthase AAGGACCTGTCTAGGTTTGATGC TGGCTTCATAGGTGACTTCCA
primary antibodies FADS1, FADS2, CPT1, GAPDH (sc-134337,
sc-98480, sc-48357, and sc-20357, respectively; Santa Cruz
Biotechnology Inc., Dallas, USA) and FASN (bs-5045R, Bioss
Inc., Massachusetts, USA). Secondary antibodies were from
Santa Cruz Biotechnology Inc., Dallas, USA. Results were
analyzed using Image Lab 5.0 (Bio-Rad laboratories GmbH,
Munich, Germany).
Analysis of Fatty Acid Composition
Cells were treated for either 24 or 48 h and harvested by adding
1mL of Dulbecco’s phosphate buffered saline to each well,
scratching the cells gently off the plate and transferring the
suspension to 2mL cups, maintaining the samples always on ice.
After centrifugation at 2,000 g and 4◦C for 5min, the supernatant
was discarded and pellet was resuspended in 200 µl of 0.2M
sodium chloride. Samples were frozen at −80◦C until further
analysis. Fatty acid composition was analyzed according to
Vauzour et al. (41) by gas chromatographywith a flame ionization
detector. Briefly, samples were lyophilized at −60◦C for 19 h
followed by 1 h at −70◦C. Fatty acid methyl esters (FAMEs)
were synthesized by incubation with 0.5M sodium methoxide
and incubated at 60◦C for 15min, followed by extraction with
acetyl chloride in methanol 1:10 (v/v) and incubation at 60◦C for
60min. One milliliter purified water, 1.5mL hexan, and sodium
sulfate were added to each sample, followed by a centrifugation
step (4◦C, 1,500 rpm for 5min). One milliliter of the supernatant
was used for further analysis. Samples were evaporated in
a SavantTM SPD131DDA SpeedVacTM Concentrator (Thermo
Fisher Scientific, Madrid, Spain) and resuspended in hexane.
FAMEs analysis was conducted in a 7820A Agilent gas
chromatograph (Agilent Technologies Spain) equipped with an
Agilent HP-23 capillary column (60m × 250µm × 0.25µm,
Agilent Technologies Spain) and helium (1.0 mL/min) as the
carrier gas. The temperature protocol was the following: initial
temperature 100◦C, ramp 8◦C/min to 145◦C (20min), ramp
5◦C/min to 195◦C (5min), ramp 5◦C to 215◦C (15min),
ramp 5◦C to 230◦C (5min). Chromatograms were recorded
and analyzed using Agilent EZChrom Elite software (Agilent
Technologies Spain) with 13:0 as the internal standard. Fatty acid
composition was calculated as a percentage of the total identified
FAMEs. The method was validated with original standards for
every fatty acid quantified. Additionally, tridecanoic acid (C13:0)
was used as internal standard and in every case a response factor
of 1 was used. The limit of quantification was calculated as being
below 0.02 mg/g dry matter and the limit of detection was 0.005
mg/mL for every fatty acid.
Statistics
Statistical analyses were performed with the software RStudio©
(RStudio, Version 1.0.136, Inc., Boston, USA) (42), using an
appropriate mixed model (43, 44). Normal distribution was
determined before the analyses with the Shapiro-Wilk-Test and
by graphical interpretation using a residual plot. The treatment
was regarded as a fixed factor and the replicate as a random
factor. Based on this model, a Pseudo R2 was calculated (45) and
an analysis of variances (ANOVA) was conducted, followed by a
post-hoc multiple comparison test of Dunnett (46) to compare
the the effects to the DMSO control or a post-hoc multiple
comparison test of Tukey to determine differences between the
means of all treatments.
RESULTS
Compound cytotoxicity was tested in a neutral red assay
(Supplementary Figure S1) and only a non-toxic dose was
applied in the following experiments.
Treating HepG2 cells with 40µM of RSV induced
transcription of FADS1 and FADS2 while 40µM of DHR
and LUN showed no effect (Figures 2A,B). On the protein level,
RSV slightly lowered FADS1 and did not have any impact on
FADS2 (Figure 2C; Supplementary Figure S3).
We conducted a second experiment to determine whether
application of external ALA influenced RSV action. In our
first attempt, we applied ALA complexed with BSA. When
applying RSV together with BSA, the induction of FADS1 and
FADS2 disappeared (Supplementary Figures S2, S4), possibly
because of RSV binding to BSA (47). Therefore, we chose
to apply ALA dissolved in EtOH for our experiments of
co-incubation with RSV. When adding EtOH-dissolved ALA,
FADS2 expression was inhibited compared to the EtOH solvent
control. Induction of FADS1 and FADS2 after 40µM RSV co-
incubation with 50µM of ALA (Figures 3A,B) was almost as
strong as when applying RSV alone (Figures 2A,B). However,
protein analysis showed a tendency toward lower FADS1
levels due to treatment with RSV and ALA (Figures 3E,F;
Supplementary Figure S5).
Resveratrol-induced CPT1 transcription was more than 10-
fold higher than in the solvent control and remained around
9-fold higher when comparing ALA with ALA and RSV
(Figure 3C). Resveratrol also induced FASN (Figure 3D). Levels
of both proteins appeared to be elevated by RSV and ALA
treatment in Western blots, albeit effects on FASN were not
significant (Figures 3G,H).
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FIGURE 2 | Effects of treating HepG2 for 24 h with 40µM of resveratrol (RSV), lunularin (LUN) or dihydro-resveratrol (DHR) on the mRNA level of (A) fatty acid
desaturase 1 (FADS1) and (B) fatty acid desaturase 2 (FADS2). Values are relative to the solvent control DMSO set to be 1.0. Expression levels were normalized to
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and are shown as means + standard error (n = 3; * P ≤ 0.05, ***P ≤ 0.001; with post-hoc multiple
comparison test of Dunnett). Effects of treating HepG2 for 24 h with 40µM of resveratrol on protein levels of FADS1 and FADS2 (C), analyzed by Western Blotting
analysis. Protein levels were normalized to the housekeeping protein GAPDH.
FIGURE 3 | Effects of treating HepG2 for 24 h with 40µM of resveratrol and 50µM α-linolenic acid (ALA) in ethanol (EtOH) or 0.125% EtOH + 0.04% DMSO solvent
control on (A) fatty acid desaturase 1 (FADS1), (B) fatty acid desaturase 2 (FADS2), (C) carnitine palmitoyltransferase 1A (CPT1), and (D) fatty acid synthase (FASN)
mRNA levels. Values are relative to DMSO + EtOH control, which was set to be 1.0. Expression levels were normalized to the housekeeping gene glyceraldehyde
3-phosphate dehydrogenase (GAPDH). n = 3; mean + standard error. Values with different superscript letters differ significantly with p-values < 0.05; with post-hoc
multiple comparison test of Tukey. Effects of treating HepG2 for 24 h with 40µM of resveratrol and 50µM ALA in EtOH or EtOH + DMSO solvent control on protein
levels of FADS1, FADS2, CPT1, or FASN (E-H), analyzed by Western Blotting analysis. Protein levels were normalized to the housekeeping protein GAPDH.
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Determining fatty acid composition with gas
chromatography, we found that in cells treated with RSV
and ALA, stearic acid and total amounts of saturated fatty acids
were enhanced. In contrast, levels of monounsaturated fatty
acids C16:1n-7, C18:1n-9c, and C18:1n-7c were decreased. Total
levels of PUFA were affected due to the addition of ALA but not
the treatment with RSV. While α-linolenic acid levels tended to
and amounts of C20:3n-3 were increased, C22:5n-3 and DHA
levels were reduced compared to non-ALA treated cells. With
exception of control ALA treated cells, EPA levels were under
the detectable limit. Fatty acid composition after 24 and 48 h was
very similar (Tables 2, 3).
When complexing ALA with BSA (Supplementary Tables S1,
S2), the impact of RSV was similar albeit less strong than with
EtOH dissolved ALA. In both experiments, total lipid contents
did not differ significantly between the treatments (data not
shown).
DISCUSSION
Resveratrol but not its metabolites LUN or DHR induced the
expression of FADS1 and FADS2 when used at a concentration
of 40µM. While the 4
′
-OH group in RSV was shown to be
important for PPARα activation (28), cell cycle and antioxidant
effects potentially further depend on the 3- and 5-OH groups
and the important trans double bond in the stilbenic skeleton
(48). Thus, the missing impacts of LUN and DHR on FADS1 and
FADS2 transcriptionmay be due to the saturated instead of trans-
unsaturated bond in both compounds and, additionally, the
absence of a 3-OH group in the structure of LUN (Figures 1C–E).
Furthermore, it has to be considered that we did not measure
intracellular concentrations of the test compounds and therefore
cannot exclude lowered bioavailability of LUN and DHR
compared to RSV.
ALA-addition to the cells did not significantly change FADS1
or FADS2 protein levels compared to non-ALA treated cells with
or without RSV.
However, as can be seen in the fatty acid analyses (Tables 2, 3),
ALA appears to be taken up by the cells. This coincides with
a previously reported dose-dependent increase of intracellular
ALA after ALA co-treatment (49). Furthermore, RSV treatment
increased ALA levels even more, which has been found in rat
hepatocytes treated with 50µM RSV (30) and Atlantic salmon
supplemented with 2.5 g/kg RSV (32).
Interestingly, in the cells, levels of total saturated fatty
acids, especially stearic acid, were increased by RSV treatment,
whereas amounts of monounsaturated fatty acids were lowered.
Application of RSV and ALA increased C20:3n-3 levels while
lowering EPA, C22:5n-3, and DHA levels. Eicosatetraenoic acid
(C20:4n-3) was not detectable in cells treated with RSV and
ALA. Based on our mRNA data for FADS2, we did not expect
TABLE 2 | Fatty acid composition (in % of total fatty acid methyl esters) of HepG2 cells treated for 24 h with 40µM of resveratrol (RSV) and 50µM of α-linolenic acid
(ALA) dissolved in ethanol (EtOH) or solvent control EtOH + DMSO.
Fatty acid Control RSV 40 µM Control + ALA RSV 40µM + ALA
14:0 2.08 ± 0.28 2.07 ± 0.22 2.09 ± 0.11 1.84 ± 0.20
16:0 21.28 ± 0.33 23.28 ± 0.51 21.99 ± 0.79 24.96 ± 4.66
18:0 7.74 ± 0.24a 15.11 ± 0.90b 7.95 ± 0.09a 13.87 ± 0.88c
20:0 0.35 ± 0.06 0.55 ± 0.14 0.32 ± 0.08 1.08 ± 0.97
Sum SFA 31.44 ± 0.14a 41.02 ± 1.20b 32.36 ± 0.73a 41.75 ± 4.99b
16:1n-7 8.61 ± 0.41a 5.37 ± 0.24b 7.59 ± 0.60c 4.08 ± 0.67d
18:1n-9c 28.13 ± 0.93a 24.86 ± 0.24b 24.42 ± 2.08b 20.38 ± 2.77c
18:1n-7c 17.70 ± 1.13a 13.45 ± 0.61b 13.96 ± 1.71b 11.00 ± 2.47c
20:1n-9 1.86 ± 0.17a 1.75 ± 0.05a 1.47 ± 0.13b 1.42 ± 0.23b
Sum MUFA 56.30 ± 2.48a 45.43 ± 0.53b 47.44 ± 4.50b 36.88 ± 6.09c
18:2n-6c 1.33 ± 0.16ac 1.41 ± 0.11ac 1.21 ± 0.08b 1.74 ± 0.17c
18:3n-3 nd nd 3.03 ± 1.88a 6.76 ± 1.34b
20:4n-6 3.67 ± 0.25ab 3.81 ± 0.26a 3.27 ± 0.21ab 3.11 ± 0.47b
20:3n-3 2.61 ± 2.01a 3.30 ± 1.02a 4.19 ± 2.96ab 5.85 ± 1.85b
20:4n-3 nd nd 0.77 ± 0.12 nd
20:5n-3 nd nd 2.43 ± 0.19 nd
22:5n-3 0.59 ± 0.08ad 0.77 ± 0.16bd 1.02 ± 0.07c 0.69 ± 0.10d
22:6n-3 3.28 ± 0.02a 3.28 ± 0.05a 3.59 ± 0.16a 2.68 ± 0.53b
Sum PUFA 9.65 ± 2.43a 10.13 ± 1.42a 16.00 ± 5.15b 15.34 ± 1.63b
EPA/DHA nv nv 0.68 ± 0.08 nv
ALA/LA nv nv 2.51 ± 1.40a 4.99 ± 1.05b
n = 3; mean ± standard deviation. Values with different superscript letters within one row significantly differ with p-values < 0.05 with post-hoc multiple comparison test of Tukey.
SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; nd: not detectable (values below detection limits); nv: no value (due to values below
detection limits). Bold values indicate most important significant findings.
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TABLE 3 | Fatty acid composition (in % of total fatty acid methyl esters) of HepG2 cells treated for 48 h with 40µM of resveratrol (RSV) and 50µM of α-linolenic acid
(ALA) dissolved in ethanol (EtOH) or solvent control EtOH + DMSO.
Fatty acid Control RSV 40 µM Control + ALA RSV 40µM + ALA
14:0 1.97 ± 0.31 1.96 ± 0.20 2.23 ± 0.12 2.09 ± 0.19
16:0 21.27 ± 1.07a 23.68 ± 0.84b 22.95 ± 0.12abc 23.22 ± 1.64c
18:0 7.53 ± 0.39a 17.07 ± 1.43b 8.36 ± 0.14a 15.73 ± 1.88b
20:0 0.34 ± 0.13a 0.58 ± 0.12b 0.27 ± 0.14a 0.62 ± 0.02b
Sum SFA 31.11 ± 1.59a 43.29 ± 2.27b 33.82 ± 0.29a 41.66 ± 3.49b
16:1n-7 8.33 ± 0.47a 4.53 ± 0.24b 7.77 ± 0.48a 3.65 ± 0.29c
18:1n-9c 28.46 ± 1.26a 25.09 ± 0.42b 26.05 ± 1.39c 21.55 ± 0.84d
18:1n-7c 19.96 ± 2.23a 12.75 ± 0.60b 15.87 ± 1.59b 11.04 ± 0.74c
20:1n-9 1.79 ± 0.05a 1.61 ± 0.09a 1.63 ± 0.08a 1.34 ± 0.19b
Sum MUFA 58.54 ± 3.98a 43.99 ± 0.31b 51.32 ± 3.49c 37.59 ± 1.37d
18:2n-6c 1.15 ± 0.56a 1.74 ± 0.68a 0.93 ± 0.12a 2.39 ± 1.42b
18:3n-3 nd nd 0.98 ± 0.52a 5.36 ± 2.05b
20:4n-6 2.77 ± 0.18a 3.25 ± 0.23b 2.59 ± 0.26b 2.88 ± 0.24c
20:3n-3 4.61 ± 3.40a 3.60 ± 2.15a 3.04 ± 1.44a 6.39 ± 2.53b
20:4n-3 nd nd 0.50 ± 0.18 nd
20:5n-3 nd nd 2.11 ± 0.53 nd
22:5n-3 0.29 ± 0.06ad 0.61 ± 0.15b 0.88 ± 0.16c 0.39 ± 0.29d
22:6n-3 2.59 ± 0.20a 2.79 ± 0.27a 3.37 ± 0.38b 2.53 ± 0.22a
Sum PUFA 7.28 ± 4.51a 9.12 ± 2.23ab 11.83 ± 3.23b 14.28 ± 4.76c
EPA/DHA nv nv 0.63 ± 0.12 nv
ALA/LA nv nv 1.06 ± 0.44a 2.24 ± 1.84b
n = 3; mean ± standard deviation. Values with different superscript letters within one row significantly differ with p-values < 0.05 with post-hoc multiple comparison test of Tukey.
SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; nd: not detectable (values below detection limits); nv: no value (due to values below
detection limits). Bold values indicate most important significant findings.
a decrease of fatty acids that are synthesized by this gene product.
However, enhanced levels of C20:3n-3 but non-detectable levels
of C20:4n-3 after application with RSV and ALA may be caused
by decreased FADS2/18-desaturase activity (1) or increased
β-oxidation (2):
1. The initial elongation of ALA may be initiated but activity of
FADS2 may be inhibited by RSV. As a multi-pass membrane
protein, FADS2 (50) possibly interacts with RSV which would
be expected to accumulate in membrane departments due to
its low solubility in aqueous environments. If RSV somehow
inhibited FADS2, it might not be able to act at the16-position
and instead, ELOV5 might induce the alternative pathway of
synthesis of n3-PUFA (13). However, 18-desaturase activity
of FADS2 may also be repressed, making C20:3n-3 potentially
an inhibitor of further fatty acid desaturation and elongation
(Figure 1). Additionally, it has been hypothesized that animals
lack 18-desaturase activity (51). Missing C20:4n-3 and no
effects on FADS2 protein levels after treatment with RSV
and EtOH-dissolved ALA supports the theory of missing
or blocked 18-desaturase activity. This may explain, why
C20:3n-3 accumulates in cells treated with ALA, although
mRNA level of FADS2 is elevated.
In contrast, detectable levels of C20:4n-3 being the product
of C20:3n-3 desaturation and C18:4n-3 elongation in control
samples indicate an induction and execution of the pathway of
n3-PUFA synthesis in the absence of RSV. In accordance with
this hypothesis of inhibited n3-PUFA synthesis after C18:3n-
3 elongation in RSV-treated cells, EPA, C22:5n-3, and DHA
levels were lowered in these samples.
2. Another explanation may be an increased β-oxidation and
thereby degradation ofmono- and polyunsaturated fatty acids.
Potential induction of β-oxidation is indicated by enhanced
CPT1 expression and protein levels, CPT1 being essential
for the passage of fatty acids through the mitochondrial
membrane (52). As reported before (53), we found RSV
to highly increase CPT1 expression. Thus, via β-oxidation,
unsaturated fatty acids may directly be metabolized to
saturated fatty acids (54). Additionally, unsaturated fatty acids
may be broken down to acetyl CoA, which in turn can be
used as a precursor for de novo synthesis of saturated fatty
acids (55). De novo synthesis of fatty acids seems to be
induced by RSV, since we found it to increase the expression
and protein levels of FASN, which is central in fatty acid
synthesis (56).
In contrast to PUFAs, saturated fatty acids are rather related
to increased inflammation and high low density lipoprotein
cholesterol levels (57, 58). However, it has been hypothesized
that stearic acid may improve fitness and lower free fatty acid
levels in fruit flies (59). In laboratory mice, dietary stearic acid
was reported as reducing visceral adipose tissue. The authors
related the effect to apoptosis induction of fat cells due to
stearic acid application, which they confirmed in vitro in cultured
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preadipocytes (60). Furthermore, stearic acid may also decrease
cholesterol absorption and inflammatory response (61, 62).
Resveratrol may reduce inflammation by lowering the levels
of high-sensitivity C-reactive protein and CC-chemokine ligand
5 in vivo (63, 64). In human plasma, these markers were
found to be modulated by different fatty acids. Stearic acid and
C18:2n-6, which we found to be increased by RSV treatment
(Tables 2, 3), may also lower high-sensitivity C-reactive protein
and CC-chemokine ligand 5 levels [reviewed by Hunter et al.
(65)]. Resveratrol-induced C18:2n-6 increase is in line with
previous results in Atlantic salmon (32). The positive effects
reported for RSV on cholesterol levels and inflammation (66, 67)
may hypothetically, in part, be related to its alteration of fatty
acid profiles. Additionally, C16:1n-7, C18:1n-9c, and C18-1n-7c,
which were decreased by RSV (Tables 2, 3), have been related
positively to the induction of inflammatory enzymes, such as
high-sensitivity C-reactive protein and CC-chemokine ligand 5
(62).
An increase of C20:3n-3 may lower inflammation since it
has been reported as dose dependently inhibiting inflammatory
markers. Of interest, this n3-fatty acid was shown to improve
skin barrier function and health in UV-irradiated hairless mice,
possibly via the nuclear factor kappa-light-chain-enhancer of
activated B cells pathway (68). However, C20:3n-3 has a lower
anti-inflammatory potential than EPA (69).
Since unsaturated carbon chains of n3-PUFA enhance
susceptibility to oxidative damage (23), RSV may hypothetically
protect cells by lowering levels of EPA, C22:5n-3, and DHA.
Of interest, RSV has been shown to induce effects similar to
caloric restriction [reviewed by Pallauf et al. (27)]. One of the
putatively life-span prolonging mechanisms, which RSV and
caloric restriction share, could possibly be lowering unsaturated
FA content of membrane lipids (70). If such a mechanism
contributed to lifespan extension, one could possibly explain
species-dependent effects of RSV on longevity, since saturation
indexes of membrane very between species [reviewed by Hector
et al. (24)].
The increase of FADS1 and FADS2 expression may be
due to RSV inducing their transcription via PPARα (8, 71).
Conversely, although we found elevated mRNA levels of FADS1
and FADS2 after RSV treatment, neither protein levels nor fatty
acid concentrations of n3-PUFA were elevated after 24 or 48 h.
We cannot exclude a long-term enhancing effect of RSV on n3-
PUFA levels. However, decreased EPA due to RSV treatment but
no influence on FADS expression was reported before for salmon
fed 1.5 g RSV per kg feed (32). This was in contrast to previous
findings in trout fed 0.3% dry matter RSV (increased n3-PUFA
but no effect on FADS2) and rat hepatocytes exposed to 50µM
RSV (increased n3-PUFA in phospholipids) (30, 31), indicating
potential species- and/or dose-specific effects.
It needs to be considered that concentrations of the test
compounds, as used in the present cell culture study, were
manifold higher than plasma concentrations reported in humans
(72).
In conclusion, albeit application of 40µM RSV to human
hepatocytes increased the expression of genes involved in
n3-PUFA synthesis, levels of EPA and DHA were reduced.
Resveratrol, furthermore, led to elevated amounts of stearic acid,
a finding, which should be validated in studies in laboratory
rodents and humans. RSV metabolites LUN and DHR did not
show an impact on FADS1 or FADS2.
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